Brokerages Set iRadimed Corporation (NASDAQ:IRMD) PT at $87.33

iRadimed Corporation (NASDAQ:IRMD) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $87.3333.

Several research analysts have commented on IRMD shares. Zacks Research raised shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 22nd. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Lake Street Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Finally, Roth Capital set a $90.00 target price on iRadimed in a research note on Friday, October 31st.

Insider Activity

In other news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $96.73, for a total transaction of $483,650.00. Following the transaction, the chief executive officer directly owned 2,287,500 shares of the company’s stock, valued at approximately $221,269,875. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John Glenn sold 15,000 shares of iRadimed stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 65,000 shares of company stock valued at $5,548,150. Insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWM LLC raised its holdings in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares during the last quarter. Quarry LP purchased a new position in shares of iRadimed in the third quarter worth $40,000. State of Alaska Department of Revenue purchased a new position in shares of iRadimed in the third quarter worth $47,000. Tower Research Capital LLC TRC lifted its holdings in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. Finally, Spire Wealth Management bought a new position in shares of iRadimed during the second quarter valued at $60,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Price Performance

Shares of NASDAQ IRMD opened at $97.45 on Friday. The business’s fifty day moving average price is $88.72 and its 200-day moving average price is $74.34. iRadimed has a one year low of $47.48 and a one year high of $98.44. The stock has a market capitalization of $1.24 billion, a PE ratio of 59.06 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The business had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities analysts expect that iRadimed will post 1.66 EPS for the current fiscal year.

iRadimed Announces Dividend

The company also recently declared a special dividend, which will be paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th will be issued a dividend of $0.50 per share. The ex-dividend date is Wednesday, December 17th. iRadimed’s dividend payout ratio is currently 41.21%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.